Company Information
Industry 科学研究和技术服务业
Company Introduction 集萃药康成立于2017年,是一家专业从事实验动物小鼠模型的研发、生产、销售及相关技术服务的高新技术企业,系亚洲小鼠突变和资源联盟企业成员以及科技部认定的国家遗传工程小鼠资源库共建单位。公司秉承“创新模型,无限可能”理念,基于实验动物创制策略与基因工程遗传修饰技术,为客户提供具有自主知识产权的商品化小鼠模型,同时开展模型定制、定制繁育、功能药效分析等一站式服务,满足客户在基因功能认知、疾病机理解析、药物靶点发现、药效筛选验证等基础研究和新药开发领域的实验动物小鼠模型相关需求。 公司使用和建立了符合国际AAALAC标准的SPF级动物设施和标准化实验动物质量管控体系,掌握了小鼠模型相关领域基因编辑、辅助生殖操作、表型验证、免疫系统人源化、靶点人源化及药效筛选、动物生产控制及无菌净化等关键技术,并以此建立了基因工程小鼠模型构建平台、创新药物筛选与表型分析平台、小鼠繁育与种质保存平台、无菌小鼠与菌群定植平台。通过以上技术平台,截至2020年末公司累计形成超过16,000种具有自主知识产权的商品化小鼠模型,品系资源数量稳居行业前列,具有核心技术与资源禀赋双重壁垒。特别地,公司开展“斑点鼠计划”,旨在预先构建小鼠所有蛋白编码基因的敲除品系库,涵盖肿瘤、代谢、免疫、发育、DNA及蛋白修饰等研究方向的基因,前瞻性地为生命科学研究提供全新工具选择与可能路径方向。 公司总部位于南京,在江苏常州、四川成都、广东佛山以及北京大兴建有子公司或分支机构,辐射国内主要市场、快速响应区域客户需求,同时设有美国子公司及欧洲办事处积极布局海外市场。公司小鼠模型年销售数量约60万只,主要涉及可用于肿瘤药效研究的免疫缺陷小鼠、人源化小鼠以及糖尿病、动脉粥样硬化、老年痴呆等小鼠疾病模型。公司目前服务客户超过1,000家,涵盖清华大学、北京大学、南京大学、中山大学、浙江大学、中国科学院、四川大学华西医院、上海交通大学医学院附属瑞金医院、中国医学科学院北京协和医院等国内一流科研院校和三甲医院,以及恒瑞医药、百济神州、信达生物、金斯瑞、药明康德、中美冠科、康龙化成、ChampionsOncology、Novartis、CharlesRiver等国内外知名创新药企和CRO研发企业。
Main Business 从事实验动物小鼠模型的研发、生产、销售及相关技术服务
Legal Representative 赵静
Top Executives
董事长:高翔
董事:杨民民,冷德嵘,王韬,赵静,李钟玉
独立董事:余波,杜鹃,肖斌卿
Top 5 Shareholder
Shareholder name Nature Holding Date
南京老岩创业投资合伙企业(有限合伙)限售股49.22%30/10/2024
青岛国药大创投资合伙企业(有限合伙)流通A股4.96%30/10/2024
江苏省产业技术研究院有限公司流通A股3.17%30/10/2024
南京生物医药谷建设发展有限公司流通A股3.16%30/10/2024
南京江北新区国有资产管理有限公司流通A股2.38%30/10/2024
Company Secretary 王逸鸥
Solicitors 江苏世纪同仁律师事务所
Auditors 致同会计师事务所(特殊普通合伙)
Tel No 025-58243997
Fax No 025-58265927
Website www.gempharmatech.com
Email ir@gempharmatech.com
Company Address
Register: 江苏省南京市江北新区学府路12号
Office: 江苏省南京市江北新区学府路12号
Listing Date 25/04/2022
Shares Capital
Shares Capital: 410,000,000
Total A Share: 410,000,000
Listed A Share: 203,931,034
Non-tradable A Share: 206,068,966
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.390
DPS(RMB)* ¥ 0.160
NBV Per Share(RMB)* ¥ 5.182
Market Capitalization(RMB) 2.835B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.